At a glance
- Originator UCB Japan
- Class Antihypertensives; Antiplatelets; Vasodilators
- Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 29 Feb 2000 Fujirebio has been acquired by UCB
- 27 Apr 1998 Profile reviewed
- 06 Jan 1997 Discontinued-Preclinical for Stroke in Japan (IV)